Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen

Nature Communications

Volumn 4, Issue , 2013, Pages

  Favrot, Lorenza ^a   Grzegorzewicz, Anna E ^b   Lajiness, Daniel H ^a   Marvin, Rachel K ^a   Boucau, Julie ^a   Isailovic, Dragan ^a   Jackson, Mary ^b   Ronning, Donald R ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN 85; CYSTEINE; EBSELEN; IODOACETAMIDE; MYCOBACTERIUM ANTIGEN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIGEN; CHEMICAL BONDING; CRYSTAL STRUCTURE; DATA ACQUISITION; DRUG RESISTANCE; INFECTIOUS DISEASE; MASS SPECTROMETRY; MEMBRANE; MICROBIAL ACTIVITY; MUTATION; OPTIMIZATION; TUBERCULOSIS;

ANTIGEN STRUCTURE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG POTENCY; DRUG RESISTANCE; ENZYME ACTIVITY; HYDROGEN BOND; IN VITRO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PROTEIN MODIFICATION; SINGLE NUCLEOTIDE POLYMORPHISM;

MYCOBACTERIUM TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, BACTERIAL; AZOLES; GENE EXPRESSION REGULATION, BACTERIAL; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; ORGANOSELENIUM COMPOUNDS; PROTEIN BINDING; PROTEIN CONFORMATION; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84889248820     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3748     Document Type: Article

References (53)

1. WHO. Global Tuberculosis Report 2012 Geneva, Switzerland, 2012)
2. Moonan, P. K. et al. Does directly observed therapy (DOT) reduce drug resistant tuberculosis? Bmc Public Health 11, 19 (2011)
3. Ford, C. B. et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 43, 482-486 (2011)
4. Loewenberg, S. India reports cases of totally drug-resistant tuberculosis. Lancet 379, 205 (2012)
5. Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994)
6. Baulard, A. R. et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 275, 28326-28331 (2000)
7. Belanger, A. E. et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl Acad. Sci. USA 93, 11919-11924 (1996)
8. Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966 (2000)
9. Matsumoto, M. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, e466 (2006)
10. Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801-804 (2009)
11. Tahlan, K. et al. SQ109 Targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797-1809 (2012)
12. Song, H., Sandie, R., Wang, Y., Andrade-Navarro, M. A. & Niederweis, M. Identification of outer membrane proteins of Mycobacterium tuberculosis. Tuberculosis (Edinb) 88, 526-544 (2008)
13. Crick, D. C. & Brennan, P. J. Biosynthesis of the Arabinogalactan-peptidoglycan Complex of Mycobacterium Tuberculosis (Amer Soc Microbiology, 1752 N Street Nw, Washington, Dc 20036-2904 USA, 2008)
14. Kaur, D., Guerin, M. E., Skovierova, H., Brennan, P. J. & Jackson, M. Chapter 2: Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Adv. Appl. Microbiol. 69, 23-78 (2009)
15. Matsunaga, I. et al. Mycolyltransferase-mediated glycolipid exchange in Mycobacteria. J. Biol. Chem. 283, 28835-28841 (2008)
16. Harth, G., Lee, B. Y., Wang, J., Clemens, D. L. & Horwitz, M. A. Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis. Infect. Immun. 64, 3038-3047 (1996)
17. Belisle, J. T. et al. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276, 1420-1422 (1997)
18. Jackson, M. et al. Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol. Microbiol. 31, 1573-1587 (1999)
19. Sanki, A. K. et al. Synthesis of methyl 5-S-alkyl-5-thio-D- arabinofuranosides and evaluation of their antimycobacterial activity. Bioorg. Med. Chem. 16, 5672-5682 (2008)
20. Sanki, A. K., Boucau, J., Umesiri, F. E., Ronning, D. R. & Sucheck, S. J. Design, synthesis and biological evaluation of sugar-derived esters, alpha-ketoesters and alpha-ketoamides as inhibitors for Mycobacterium tuberculosis antigen 85C. Mol. Biosyst. 5, 945-956 (2009)
21. Sanki, A. K., Boucau, J., Ronning, D. R. & Sucheck, S. J. Antigen 85C-mediated acyl-transfer between synthetic acyl donors and fragments of the arabinan. Glycoconj. J. 26, 589-596 (2009)
22. Anderson, D. H., Harth, G., Horwitz, M. A. & Eisenberg, D. An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the Mycobacterium tuberculosis 30 kDa major secretory protein (Antigen 85B), a mycolyl transferase. J. Mol. Biol. 307, 671-681 (2001)
23. Ronning, D. R. et al. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat. Struct. Biol. 7, 141-146 (2000)
24. Ronning, D. R., Vissa, V., Besra, G. S., Belisle, J. T. & Sacchettini, J. C. Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity. J. Biol. Chem. 279, 36771-36777 (2004)
25. da Silva, P. E., Von Groll, A., Martin, A. & Palomino, J. C. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 63, 1-9 (2011)
26. Armitige, L. Y., Jagannath, C., Wanger, A. R. & Norris, S. J. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect. Immun. 68, 767-778 (2000)
27. Warrier, T. et al. Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob. Agents Chemother. 56, 1735-1743 (2012)
28. Lu, J. et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J 27, 1394-1403 (2013)
29. Backus, K. M. et al. Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. Nat. Chem. Biol. 7, 228-235 (2011)
30. Zhang, J., Chung, T. D. Y. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999)
31. Xu, K. et al. Study of highly selective and efficient thiol derivatization using selenium reagents by mass spectrometry. Anal. Chem. 82, 6926-6932 (2010)
32. Elamin, A. A., Stehr, M., Oehlmann, W. & Singh, M. The mycolyltransferase 85A, a putative drug target of Mycobacterium tuberculosis: development of a novel assay and quantification of glycolipid-status of the mycobacterial cell wall. J. Microbiol. Methods. 79, 358-363 (2009)
33. Boucau, J., Sanki, A. K., Voss, B. J., Sucheck, S. J. & Ronning, D. R. A coupled assay measuring Mycobacterium tuberculosis antigen 85C enzymatic activity. Anal. Biochem. 385, 120-127 (2009)
34. Umesiri, F. E., Sanki, A. K., Boucau, J., Ronning, D. R. & Sucheck, S. J. Recent advances toward the inhibition of mAG and LAM synthesis in Mycobacterium tuberculosis. Med. Res. Rev. 30, 290-326 (2010)
35. Hernick, M. Mycothiol: a target for potentiation of rifampin and other antibiotics against Mycobacterium tuberculosis. Expert. Rev. Anti. Infect. Ther. 11, 49-67 (2013)
36. Grzegorzewicz, A. E. et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8, 334-341 (2012)
37. Ibrahim, D. A. et al. Design, synthesis, and x-ray analysis of a glycoconjugate bound to Mycobacterium tuberculosis antigen 85C. Bioconjug. Chem. 23, 2403-2416 (2012)
38. Burmeister, W. P. Structural changes in a cryo-cooled protein crystal owing to radiation damage. Acta. Crystallogr. D. Biol. Crystallogr. 56(Pt 3): 328-341 (2000)
39. Ravelli, R. B. & McSweeney, S. M. The fingerprint that X-rays can leave on structures. Structure 8, 315-328 (2000)
40. Weik, M. et al. Specific chemical and structural damage to proteins produced by synchrotron radiation. Proc. Natl Acad. Sci. USA 97, 623-628 (2000)
41. Leiros, H. K., McSweeney, S. M. & Smalas, A. O. Atomic resolution structures of trypsin provide insight into structural radiation damage. Acta. Crystallogr. D. Biol. Crystallogr. 57(Pt 4): 488-497 (2001)
42. Carugo, O. & Djinovic Carugo, K. When X-rays modify the protein structure: radiation damage at work. Trends. Biochem. Sci. 30, 213-219 (2005)
43. Trefzer, C. et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase DprE1. J. Am. Chem. Soc. 134, 912-915 (2012)
44. Batt, S. M. et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. USA 109, 11354-11359 (2012)
45. Neres, J. et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 4, 150ra121 (2012)
46. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998)
47. Puech, V. et al. Evidence for a partial redundancy of the fibronectinbinding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis. Mol. Microbiol. 44, 1109-1122 (2002)
48. Wilson, R. A., Maughan, W. N., Kremer, L., Besra, G. S. & Futterer, K. The structure of Mycobacterium tuberculosis MPT51 (FbpC1) defines a new family of non-catalytic alpha/beta hydrolases. J. Mol. Biol. 335, 519-530 (2004)
49. Gasteiger, E. et al. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic. Acids Res. 31, 3784-3788 (2003)
50. Stadthagen, G. et al. p-Hydroxybenzoic acid synthesis in Mycobacterium tuberculosis. J. Biol. Chem. 280, 40699-40706 (2005)
51. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997)
52. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta. Crystallogr. D. Biol. Crystallogr. 66(Pt 2): 213-221 (2010)
53. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta. Crystallogr. D. Biol. Crystallogr. 66(Pt 4): 486-501 (2010)